In focus · trending topic

antiobiotic resistance

2 stories · following the connections

Arch Biopartners Announces Issuance of U.S. Patent for Its Novel Antibacterial Drug AB569, Designed to Target Chronic Infection and Antibiotic Resistance

By Nasdaq OMXMar 27, 2018, 1:08 PM UTC

Arch Biopartners Announces AB569 Phase I Human Trial Begins Patient Recruitment and Enrollment Stage

By Nasdaq OMXFeb 13, 2018, 1:03 PM UTC